Two Sigma Advisers’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-590,676
| Closed | -$8.41M | – | 797 |
|
|
2025
Q4 | $8.41M | Buy |
590,676
+245,300
| +71% | +$2.41M | 0.02% | 604 |
|
|
2025
Q3 | $2.72M | Sell |
345,376
-551,200
| -61% | -$3.92M | 0.01% | 991 |
|
|
2025
Q2 | $5.14M | Sell |
896,576
-136,700
| -13% | -$882K | 0.01% | 729 |
|
|
2025
Q1 | $8.43M | Buy |
1,033,276
+921,300
| +823% | +$8.53M | 0.02% | 592 |
|
|
2024
Q4 | $1.05M | Buy |
111,976
+52,000
| +87% | +$540K | ﹤0.01% | 1432 |
|
|
2024
Q3 | $641K | Sell |
59,976
-23,700
| -28% | -$258K | ﹤0.01% | 1604 |
|
|
2024
Q2 | $830K | Buy |
83,676
+59,100
| +240% | +$607K | ﹤0.01% | 1649 |
|
|
2024
Q1 | $290K | Buy |
+24,576
| New | +$314K | ﹤0.01% | 2081 |
|
|
2023
Q3 | – | Sell |
-235,676
| Closed | -$2.96M | – | 2448 |
|
|
2023
Q2 | $2.96M | Sell |
235,676
-201,000
| -46% | -$2.39M | 0.01% | 999 |
|
|
2023
Q1 | $4.84M | Sell |
436,676
-82,200
| -16% | -$1.01M | 0.01% | 823 |
|
|
2022
Q4 | $6.34M | Sell |
518,876
-209,500
| -29% | -$2.36M | 0.02% | 681 |
|
|
2022
Q3 | $7.6M | Buy |
728,376
+112,000
| +18% | +$1.25M | 0.02% | 574 |
|
|
2022
Q2 | $6.62M | Sell |
616,376
-15,200
| -2% | -$125K | 0.02% | 649 |
|
|
2022
Q1 | $5.98M | Sell |
631,576
-224,000
| -26% | -$2.1M | 0.02% | 726 |
|
|
2021
Q4 | $9.88M | Buy |
855,576
+503,500
| +143% | +$5.61M | 0.02% | 504 |
|
|
2021
Q3 | $3.36M | Sell |
352,076
-659,400
| -65% | -$6.75M | 0.01% | 976 |
|
|
2021
Q2 | $9.75M | Sell |
1,011,476
-542,300
| -35% | -$5.29M | 0.03% | 575 |
|
|
2021
Q1 | $15.4M | Buy |
1,553,776
+507,600
| +49% | +$7.86M | 0.04% | 430 |
|
|
2020
Q4 | $24.2M | Buy |
1,046,176
+688,200
| +192% | +$14.1M | 0.06% | 294 |
|
|
2020
Q3 | $5.05M | Buy |
357,976
+214,100
| +149% | +$3.12M | 0.01% | 766 |
|
|
2020
Q2 | $2.17M | Buy |
143,876
+122,976
| +588% | +$1.5M | 0.01% | 1164 |
|
|
2020
Q1 | $193K | Sell |
20,900
-30,476
| -59% | -$290K | ﹤0.01% | 2178 |
|
|
2019
Q4 | $500K | Buy |
+51,376
| New | +$470K | ﹤0.01% | 1875 |
|
|
2018
Q2 | – | Sell |
-16,000
| Closed | -$241K | – | 2407 |
|
|
2018
Q1 | $241K | Sell |
16,000
-1,200
| -7% | -$18.3K | ﹤0.01% | 2090 |
|
|
2017
Q4 | $248K | Buy |
17,200
+1,800
| +12% | +$24.7K | ﹤0.01% | 2018 |
|
|
2017
Q3 | $232K | Buy |
+15,400
| New | +$204K | ﹤0.01% | 2011 |
|
|
2016
Q1 | – | Sell |
-10,500
| Closed | -$102K | – | 2065 |
|
|
2015
Q4 | $102K | Buy |
+10,500
| New | +$94.6K | ﹤0.01% | 1772 |
|
|
2015
Q1 | – | Sell |
-207,673
| Closed | -$1.73M | – | 2074 |
|
|
2014
Q4 | $1.73M | Sell |
207,673
-1,400
| -0.7% | -$9.61K | 0.01% | 892 |
|
|
2014
Q3 | $1.24M | Buy |
209,073
+194,100
| +1,296% | +$1.02M | 0.01% | 1023 |
|
|
2014
Q2 | $50K | Buy |
+14,973
| New | +$35.1K | ﹤0.01% | 2394 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Two Sigma Advisers's FOLD Position: Q1 2026 in Review
Two Sigma Advisers sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 590,676 shares — an estimated $8.41M sold.
Two Sigma Advisers first reported a position in FOLD in Q2 2014 and held it in 30 quarters. The position peaked at $24.2M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Two Sigma Advisers reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 590,676 Amicus Therapeutics shares in Q1 2026, an estimated $8.41M.
- Two Sigma Advisers first reported a position in Amicus Therapeutics in Q2 2014 and held it in 30 quarters.
- Two Sigma Advisers's Amicus Therapeutics position peaked at $24.2M in Q4 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.